BBOT PE Ratio & Valuation,Is BBOT Overvalued — Intellectia
BBOT Relative Valuation
BBOT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BBOT is overvalued; if below, it's undervalued.
Historical Valuation
BridgeBio Oncology Therapeutics Inc(BBOT) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of-5.94.The fair price ofBridgeBio Oncology Therapeutics Inc(BBOT)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：11.92
Fair
-5.59
PE
1Y
3Y
5Y
Trailing
Forward
-2.44
EV/EBITDA
BridgeBio Oncology Therapeutics Inc. (BBOT) has a current EV/EBITDA of -2.44. The 5-year average EV/EBITDA is -1.08. The thresholds are as follows: Strongly Undervalued below -4.78, Undervalued between -4.78 and -2.93, Fairly Valued between 0.76 and -2.93, Overvalued between 0.76 and 2.61, and Strongly Overvalued above 2.61. The current Forward EV/EBITDA of -2.44 falls within the Historic Trend Line -Fairly Valued range.
-2.57
EV/EBIT
BridgeBio Oncology Therapeutics Inc. (BBOT) has a current EV/EBIT of -2.57. The 5-year average EV/EBIT is -5.25. The thresholds are as follows: Strongly Undervalued below -9.11, Undervalued between -9.11 and -7.18, Fairly Valued between -3.32 and -7.18, Overvalued between -3.32 and -1.39, and Strongly Overvalued above -1.39. The current Forward EV/EBIT of -2.57 falls within the Overvalued range.
0.00
PS
BridgeBio Oncology Therapeutics Inc. (BBOT) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-8.85
P/OCF
BridgeBio Oncology Therapeutics Inc. (BBOT) has a current P/OCF of -8.85. The 5-year average P/OCF is -7.37. The thresholds are as follows: Strongly Undervalued below -12.44, Undervalued between -12.44 and -9.90, Fairly Valued between -4.84 and -9.90, Overvalued between -4.84 and -2.31, and Strongly Overvalued above -2.31. The current Forward P/OCF of -8.85 falls within the Historic Trend Line -Fairly Valued range.
-8.89
P/FCF
BridgeBio Oncology Therapeutics Inc. (BBOT) has a current P/FCF of -8.89. The 5-year average P/FCF is -7.43. The thresholds are as follows: Strongly Undervalued below -12.53, Undervalued between -12.53 and -9.98, Fairly Valued between -4.87 and -9.98, Overvalued between -4.87 and -2.32, and Strongly Overvalued above -2.32. The current Forward P/FCF of -8.89 falls within the Historic Trend Line -Fairly Valued range.
BridgeBio Oncology Therapeutics Inc (BBOT) has a current Price-to-Book (P/B) ratio of 2.10. Compared to its 3-year average P/B ratio of 1.05 , the current P/B ratio is approximately 100.23% higher. Relative to its 5-year average P/B ratio of 1.05, the current P/B ratio is about 100.23% higher. BridgeBio Oncology Therapeutics Inc (BBOT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.03%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.03% , the current FCF yield is about -100.00% lower.
2.10
P/B
Median3y
1.05
Median5y
1.05
-9.09
FCF Yield
Median3y
-14.03
Median5y
-14.03
Competitors Valuation Multiple
The average P/S ratio for BBOT's competitors is 0.00, providing a benchmark for relative valuation. BridgeBio Oncology Therapeutics Inc Corp (BBOT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BBOT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BBOT in the past 1 year is driven by Unknown.
Is BridgeBio Oncology Therapeutics Inc (BBOT) currently overvalued or undervalued?
BridgeBio Oncology Therapeutics Inc(BBOT)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of-5.94.The fair price of BridgeBio Oncology Therapeutics Inc(BBOT)is betweentoaccording to relative valuation methord.
What is BridgeBio Oncology Therapeutics Inc (BBOT) fair value?
BBOT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BridgeBio Oncology Therapeutics Inc (BBOT) is between to according to relative valuation methord.
How does BBOT's valuation metrics compare to the industry average?
The average P/S ratio for BBOT's competitors is 0.00, providing a benchmark for relative valuation. BridgeBio Oncology Therapeutics Inc Corp (BBOT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for BridgeBio Oncology Therapeutics Inc (BBOT) as of Dec 17 2025?
As of Dec 17 2025, BridgeBio Oncology Therapeutics Inc (BBOT) has a P/B ratio of 2.10. This indicates that the market values BBOT at 2.10 times its book value.
What is the current FCF Yield for BridgeBio Oncology Therapeutics Inc (BBOT) as of Dec 17 2025?
As of Dec 17 2025, BridgeBio Oncology Therapeutics Inc (BBOT) has a FCF Yield of 0.00%. This means that for every dollar of BridgeBio Oncology Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for BridgeBio Oncology Therapeutics Inc (BBOT) as of Dec 17 2025?
As of Dec 17 2025, BridgeBio Oncology Therapeutics Inc (BBOT) has a Forward P/E ratio of -5.59. This means the market is willing to pay $-5.59 for every dollar of BridgeBio Oncology Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BridgeBio Oncology Therapeutics Inc (BBOT) as of Dec 17 2025?
As of Dec 17 2025, BridgeBio Oncology Therapeutics Inc (BBOT) has a Forward P/S ratio of 0.00. This means the market is valuing BBOT at $0.00 for every dollar of expected revenue over the next 12 months.
